Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2016-12-14 Director's Dealing
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2016-12-14 English
FORM 4
Director's Dealing
2016-12-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a short filing (2950 characters) that primarily furnishes a press release about presentations at a scientific meeting. It explicitly states the press release is furnished as an exhibit and is not incorporated by reference into other filings. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, nor is it an earnings release or management discussion. It is a regulatory announcement of an event (presentation of clinical trial data) rather than a full report. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2016-12-05 English
FORM 10-Q
Interim / Quarterly Report 9M 2016
2016-11-03 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce specific events or updates. The text indicates that the company issued a press release about clinical trial data and attached a presentation as exhibits. There is no detailed financial data or comprehensive report content; rather, it is an announcement of other materials (press release and presentation). The document length is short (2821 characters), and it primarily serves to notify about the press release and presentation filing. Therefore, this fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-10-26 English
SCHEDULE 13D/A
Major Shareholding Notification
2016-09-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.